Literature DB >> 34752508

Cost-Sharing Requirements for the Herpes Zoster Vaccine in Adults Aged 60.

Casey R Tak1,2, Jaewhan Kim3, Karen Gunning3, Catherine M Sherwin4,5, Nancy A Nickman3, Joseph E Biskupiak3.   

Abstract

Background: Rates of zoster vaccination in US adults aged 60+ were approximately 30.6% in 2015. Out-of-pocket cost-sharing has been identified as a major barrier to vaccination for patients. To date, herpes zoster vaccine cost-sharing requirements for adults aged 60 to 64 has not been described. Objective: Compare the cost-sharing requirements for zoster vaccination in adults aged 60 to 64 and adults aged 65+.
Methods: A retrospective cohort design examined pharmacy claims for zoster vaccination from the Utah All Payer Claims Database for adults aged 60+. Descriptive statistics and a 2-part cost model compared cost-sharing requirements for adults aged 60 to 64 and adults 65+.
Results: Of the 30 293 zoster vaccine claims, 13 398 (45.8%) had no cost-sharing, 1716 (5.9%) had low cost-sharing (defined as $1 to less than $30), and 14 133 (48.3%) had high cost-sharing (defined as $30 or more). In the cost models, adults aged 65+ had higher odds of any cost-sharing (odds ratio = 39.86) and 29% higher cost-sharing as compared with adults aged 60 to 64. Conclusions: Adults aged 60 to 64 encounter lower cost-sharing requirements than adults aged 65+. Providers should be cognizant of this dynamic and encourage zoster vaccination prior to the age of 65.
© The Author(s) 2019.

Entities:  

Keywords:  adults; cost-sharing; elderly; herpes zoster; immunization; out-of-pocket payment; pharmacy; shingles; vaccine

Year:  2019        PMID: 34752508      PMCID: PMC6726872          DOI: 10.1177/8755122519860074

Source DB:  PubMed          Journal:  J Pharm Technol        ISSN: 1549-4810


  16 in total

Review 1.  Methods for analyzing health care utilization and costs.

Authors:  P Diehr; D Yanez; A Ash; M Hornbrook; D Y Lin
Journal:  Annu Rev Public Health       Date:  1999       Impact factor: 21.981

2.  Meeting Abstracts - Nexus 2015.

Authors: 
Journal:  J Manag Care Spec Pharm       Date:  2015-10

Review 3.  Medicare part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2008.

Authors:  Ronnie Depue; Joann Stubbings
Journal:  J Manag Care Pharm       Date:  2008 Jan-Feb

4.  Meeting Abstracts - Annual Meeting 2016.

Authors: 
Journal:  J Manag Care Spec Pharm       Date:  2016-04

5.  Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.

Authors:  Songkai Yan; Maral DerSarkissian; Rachel H Bhak; Patrick Lefebvre; Mei Sheng Duh; Girishanthy Krishnarajah
Journal:  Curr Med Res Opin       Date:  2018-01-10       Impact factor: 2.580

Review 6.  Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia.

Authors:  D Gilden
Journal:  J Intern Med       Date:  2011-02-23       Impact factor: 8.989

7.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Rafael Harpaz; Ismael R Ortega-Sanchez; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2008-06-06

8.  Update on recommendations for use of herpes zoster vaccine.

Authors:  Craig M Hales; Rafael Harpaz; Ismael Ortega-Sanchez; Stephanie R Bialek
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-08-22       Impact factor: 17.586

Review 9.  A systematic review of the cost effectiveness of herpes zoster vaccination.

Authors:  Thomas D Szucs; Alena M Pfeil
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.558

10.  Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.

Authors:  Kathleen L Dooling; Angela Guo; Manisha Patel; Grace M Lee; Kelly Moore; Edward A Belongia; Rafael Harpaz
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-26       Impact factor: 17.586

View more
  1 in total

1.  Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine.

Authors:  Laura P Hurley; Sean T O'Leary; Kathleen Dooling; Tara C Anderson; Lori A Crane; Jessica R Cataldi; Michaela Brtnikova; Brenda L Beaty; Carol Gorman; Angela Guo; Megan C Lindley; Allison Kempe
Journal:  J Gen Intern Med       Date:  2022-07-06       Impact factor: 6.473

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.